Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dora Buonfrate

Showing results (1-10 of 183) with videos related to

Pageof 19
Sort By:
The Lancet. Infectious Diseases|November 10, 2022
Alternative treatment strategies for trichuriasisDora Buonfrate
The Lancet. Infectious Diseases|January 13, 2025
Albendazole and ivermectin co-formulation for soil-transmitted helminthiasesDora Buonfrate
Lancet (London, England)|August 17, 2024
Emodepside against hookwormDora Buonfrate
Chest|May 9, 2021
Standard Dose Ivermectin for COVID-19Dora Buonfrate, Zeno Bisoffi
The Lancet. Infectious Diseases|April 2, 2021
Moxidectin: an ally to ivermectin for treating Strongyloides stercoralis?Zeno Bisoffi, Dora Buonfrate
Evidence-Based Medicine|April 27, 2016
Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectivelyDora Buonfrate, Federico Gobbi
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2018
Is Ivermectin Ineffective for Strongyloidiasis?Dora Buonfrate, Zeno Bisoffi
The Lancet. Global Health|August 9, 2014
When fever is not malariaZeno Bisoffi, Dora Buonfrate
International Journal of Antimicrobial Agents|March 24, 2022
Reply to: Viral load reduction and high-dose ivermectin in early treatment: a reappraisalDora Buonfrate, Eliana Rulli, Zeno Bisoffi
The Journal of Antimicrobial Chemotherapy|January 10, 2016
Comment on: Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literatureDora Buonfrate, Federico Gobbi, Zeno Bisoffi
Pageof 19

Showing results (1-10 of 183) with videos related to

Sort By:
Pageof 19
The Lancet. Infectious Diseases|November 10, 2022
Alternative treatment strategies for trichuriasisDora Buonfrate
The Lancet. Infectious Diseases|January 13, 2025
Albendazole and ivermectin co-formulation for soil-transmitted helminthiasesDora Buonfrate
Lancet (London, England)|August 17, 2024
Emodepside against hookwormDora Buonfrate
Chest|May 9, 2021
Standard Dose Ivermectin for COVID-19Dora Buonfrate, Zeno Bisoffi
The Lancet. Infectious Diseases|April 2, 2021
Moxidectin: an ally to ivermectin for treating Strongyloides stercoralis?Zeno Bisoffi, Dora Buonfrate
Evidence-Based Medicine|April 27, 2016
Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectivelyDora Buonfrate, Federico Gobbi
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2018
Is Ivermectin Ineffective for Strongyloidiasis?Dora Buonfrate, Zeno Bisoffi
The Lancet. Global Health|August 9, 2014
When fever is not malariaZeno Bisoffi, Dora Buonfrate
International Journal of Antimicrobial Agents|March 24, 2022
Reply to: Viral load reduction and high-dose ivermectin in early treatment: a reappraisalDora Buonfrate, Eliana Rulli, Zeno Bisoffi
The Journal of Antimicrobial Chemotherapy|January 10, 2016
Comment on: Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literatureDora Buonfrate, Federico Gobbi, Zeno Bisoffi
Pageof 19